John T. Kalyvas

John T. Kalyvas

Auto-generated profile, based on publicly available information

John T. Kalyvas

Department of Chemistry, School of Physics, Chemistry and Earth Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Open access
YWYifei Wang
Yifei Wang
JKJohn T. Kalyvas
John T. Kalyvas
JEJack D. Evans
Jack D. Evans
LULuis Toronjo Urquiza
Luis Toronjo Urquiza
JHJohn R. Horsley
John R. Horsley
Andrew AbellAndrew Abell
Andrew Abell
The rise of multidrug-resistant bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA), necessitates the development of new antibacterial therapies. Antimicrobial peptides offer a promising alternative to conventional antibiotics due to their unique mechanisms of action. Gramicidin S exhibits potent bactericidal activity against S. aureus, however, high haemolytic toxicity currently limits its application to topical use. A new series of gramicidin S analogues is presented with rational modifications to the β-turn and β-strand regions, to reduce haemolytic and nephrotoxic effects, while preserving antibacterial potency. The minimum inhibitory concentration (MIC) for each analogue was determined against benchmark methicillin-sensitive S. aureus (MSSA) and MRSA clinical isolates, with toxicity characterised in vitro using human red blood cells and human embryonic kidney cells (HEK-293). Peptide 12 demonstrated a significant two-fold increase in antibacterial activity against both MSSA and MRSA (MIC: 2 μg/mL) compared to gramicidin S (MIC: 4 μg/mL), albeit with increased cytotoxicity. Similarly, peptide 15 showed exceptional efficacy (MIC: 3 μg/mL), but with reduced cytotoxicity, culminating in a two-fold improvement to the therapeutic index (TI) of gramicidin S. Peptides 14 (HC50: 50.48 ± 1.15 μg/mL, IC50: 38.09 μg/mL) and 16 (HC50: 84.09 ± 1.02 μg/mL, IC50: 12.60 μg/mL) also significantly reduced haemolytic toxicity and nephrotoxicity, compared to gramicidin S (HC50: 12.34 ± 0.27 μg/mL, IC50: 6.45 μg/mL). Detailed NMR, CD and computational modelling were used to provide critical insights into how molecular conformation influences both antibacterial potency and cytotoxicity. Collectively, these results expand the therapeutic window of gramicidin S by up to 12-fold, with negligible cytotoxicity observed at concentrations well beyond the acceptable safety threshold, which indicates the potential for safe systemic administration in the treatment of infection caused by resistant pathogens.